Alpert Evgenia, Gruzman Arie, Tennenbaum Tamar, Sasson Shlomo
Department of Pharmacology, Faculty of Medicine, The Hebrew University, Jerusalem 91120, Israel.
Biochem Pharmacol. 2007 Feb 1;73(3):368-77. doi: 10.1016/j.bcp.2006.10.008. Epub 2006 Oct 13.
Selective inhibitors of cyclooxygenase-2 (prostaglandin-endoperoxide synthase-2; COX-2) augment the rate of hexose uptake in myotubes by recruiting glucose transporter-4 (GLUT-4) to the plasma membrane in an insulin- and AMPKalpha-independent manner [Alpert E, Gruzman A, Lardi-Studler B, Cohen G, Reich R, Sasson S. Cyclooxygenase-2 (PTGS2) inhibitors augment the rate of hexose transport in L6 myotubes in an insulin- and AMPKalpha-independent manner. Diabetologia 2006;49:562-70]. We aimed at elucidating the molecular interactions that mediate this effect of COX-2 inhibitors in L6 myotubes. The effects of the inhibitors niflumic acid, nimesulide and rofecoxib on activities and phosphorylation state of key proteins in the insulin transduction pathway were determined. These inhibitors did not induce specific tyrosine phosphorylation in IRS-1, could not assemble a functional IRS-PI3K-PKB/Akt complex and did not activate GSK3alpha/beta, JNK1/2, ERK1/2, p38-MAPK or c-Cbl by site-specific phosphorylation(s). Yet, like insulin, they activated mTOR and induced downstream threonine phosphorylation in p70S6K and 4EBP1. However, rapamycin, which inhibits mTOR enzymatic activity, did not interfere with COX-2 inhibitor-induced stimulation of hexose uptake in myotube. Thus, mTOR activation was not required for COX-2 inhibitor-dependent augmentation of hexose transport in myotubes. Because PKCdelta has also been shown to activate mTOR, we asked whether COX-2 inhibitors activate mTOR by a prior activation of PKCdelta. Indeed, all three inhibitors induced tyrosine phosphorylation in PKCdelta and stimulated its kinase activity. Moreover, pharmacological inhibition of PKCdelta or the expression of a dominant-negative form of PKCdelta in myotubes completely abolished COX-2 inhibitor-dependent stimulation of hexose uptake. This study shows that selective COX-2 inhibitors activate a unique PKCdelta-dependent pathway to increase GLUT-4 abundance in the plasma membrane of myotubes and augment the rate of hexose transport.
环氧化酶-2(前列腺素内过氧化物合酶-2;COX-2)的选择性抑制剂通过以不依赖胰岛素和AMPKα的方式将葡萄糖转运蛋白-4(GLUT-4)募集到质膜,从而提高肌管中己糖的摄取速率[阿尔珀特E、格鲁兹曼A、拉尔迪-施图德勒B、科恩G、赖希R、萨松S。环氧化酶-2(PTGS2)抑制剂以不依赖胰岛素和AMPKα的方式提高L6肌管中己糖转运的速率。《糖尿病学》2006年;49:562 - 70]。我们旨在阐明介导COX-2抑制剂在L6肌管中这种作用的分子相互作用。测定了尼氟酸、尼美舒利和罗非昔布等抑制剂对胰岛素转导途径中关键蛋白活性和磷酸化状态的影响。这些抑制剂不会诱导IRS-1中的特异性酪氨酸磷酸化,无法组装功能性的IRS-PI3K-PKB/Akt复合物,也不会通过位点特异性磷酸化激活GSK3α/β、JNK1/2、ERK1/2、p38-MAPK或c-Cbl。然而,与胰岛素一样,它们激活了mTOR并诱导了p70S6K和4EBP1下游的苏氨酸磷酸化。但是,抑制mTOR酶活性的雷帕霉素并不干扰COX-2抑制剂诱导的肌管中己糖摄取的刺激。因此,mTOR激活并非COX-2抑制剂依赖性增加肌管中己糖转运所必需。因为PKCδ也已被证明可激活mTOR,所以我们询问COX-2抑制剂是否通过先激活PKCδ来激活mTOR。事实上,所有三种抑制剂都诱导了PKCδ中的酪氨酸磷酸化并刺激了其激酶活性。此外,对PKCδ的药理学抑制或在肌管中表达PKCδ的显性负性形式完全消除了COX-2抑制剂依赖性的己糖摄取刺激。这项研究表明,选择性COX-2抑制剂激活了一条独特的PKCδ依赖性途径,以增加肌管质膜中GLUT-4的丰度并提高己糖转运速率。